Profile
The Gomez-Gutierrez Laboratory is primarily interested in microbial-based cancer therapy. Dr. Gomez-Gutierrez, PhD focuses on investigating how virus- and bacteria-based therapies can be used to stop tumorigenesis and induce oncolysis and/or immune responses in cancers when conventional therapy is inadequate. Two microorganisms are being studied: the first is a conditionally replicating adenovirus (CRAd) also known as oncolytic adenovirus (OAd); the second is the lactic acid bacteria Lactococcus lactis (L. lactis), which is generally regarded as a safe (GRAS) organism and is used in dairy industry to make cheese and yogurt. The former study was funded with an NIH/NCI exploratory/developmental grant R21CA210202 and currently supported by Burroughs Wellcome Fund.
Academic Information
Office
1030 Hitt Street
Columbia, MO 65211
United States
Research Interests
- Microbial based immunotherapies
- Cancer immunology and imaging
Areas of Expertise
- recombinant probiotic bacterium
- oncolytic adenovirus-based cancer virotherapy
- advanced molecular imaging
- multispectral optoacoustic tomography
Education & Training
Post-Graduate School
2006, PhD, University of Nuevo León
2001, BS University of Nuevo León
Degrees
2006 PhD, Autonomous University of Nuevo Leon
Awards & Honors
- 2025 Health Science Research Day, First Place, Poster Presentation, Translational Science Category II. Rubio-Infante N (Presenter), Gomez-Gutierrez JG (Project Director).
- 2025 AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award
- 2022 AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award
In the News
Publications
- Ramos-Gonzalez MR, Sirpu Natesh N, Rachagani S, Amos-Landgraf J, Shirwan H, Yolcu ES, Gomez-Gutierrez JG, et al.
Establishment of Translational Luciferase-Based Cancer Models to Evaluate Antitumoral Therapies.
Int J Mol Sci. 2024 Sep 27;25(19):10418. - Ramos-Gonzalez MR, Tarique M, Batra L, Arguc F, Garza-Morales R, Shirwan H, Yolcu ES, Gomez-Gutierrez JG.
Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.
Vaccines (Basel). 2024 Mar 21;12(3):340. - Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, Ramirez-Avila NE, Loera-Arias MJ, Gomez-Gutierrez JG, et al.
An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model.
Vaccines (Basel). 2021 Feb 12;9(2):149. - Lanceta L, O’Neill C, Lypova N, Li X, Rouchka E, Waigel S, et al.
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells.
Genes (Basel). 2020 Apr 24;11(4):467. - Garza-Morales R, Perez-Trujillo JJ, Martinez-Jaramillo E, Saucedo-Cardenas O, Loera-Arias MJ, Garcia-Garcia A, et al.
A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model.
Cancers (Basel). 2019 Jan 15;11(1):96.